Who is sponsoring NCT04583982?

NCT04583982 is sponsored by Adaptive Biotechnologies.

What drugs are being tested in NCT04583982?

Interventions in NCT04583982: T-Detect™ SARS-CoV-2 Assay.

What condition does NCT04583982 study?

NCT04583982 studies Coronavirus Disease (COVID-19), SARS-CoV-2 Infection.

Is NCT04583982 still recruiting?

NCT04583982 is currently completed. Last updated 15 April 2022.

Last reviewed 2022-04-15 · How we verify

NCT04583982

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ImmuneSense™ COVID-19 Study

Completed Last updated 15 April 2022

What this trial tests

trial testing T-Detect™ SARS-CoV-2 Assay in Coronavirus Disease (COVID-19) in 180 participants. Completed in 4 December 2020.

Timeline

9 October 2020

Primary endpoint
4 December 2020

4 December 2020

Quick facts

Lead sponsor	Adaptive Biotechnologies
Status	Completed
Study type	OBSERVATIONAL
Enrollment	180
Start date	9 October 2020
Primary completion	4 December 2020
Estimated completion	4 December 2020
Sites	1 location across United States

Drugs / interventions tested

T-Detect™ SARS-CoV-2 Assay

Conditions studied

Coronavirus Disease (COVID-19) — all drugs for Coronavirus Disease (COVID-19) →
SARS-CoV-2 Infection — all drugs for SARS-CoV-2 Infection →

Sponsor

Adaptive Biotechnologies — full company profile →

Who can join

Adults 18 to 89, any sex, with Coronavirus Disease (COVID-19) or SARS-CoV-2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronavirus disease is of an urgent global priority. The purpose of ImmuneSense™ COVID-19 study is to evaluate the clinical performance and to provide data for clinical validation for the T-Detect™ SARS-CoV-2 (previously referred to as immunoSEQ Dx SARS-CoV-2) Assay in support of Adaptive's Emergency Use Authorization (EUA) request for T-Detect™ SARS-CoV-2 and secondary aims. This assay is intended to detect immune response to the virus that causes coronavirus disease (COVID-19), SARS-CoV-2. This is critically important because the immune system may be able to tell us important information about how our own bodies detect and respond to the disease that current tests cannot.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Dalai SC, Dines JN, Snyder TM, Gittelman RM, et al · · 2022 · cited 39× · PMID 35521791 · DOI 10.1093/cid/ciac353
T cell immunity is key to the pandemic endgame: How to measure and monitor it.
Schwarz M, Mzoughi S, Lozano-Ojalvo D, Tan AT, et al · · 2022 · cited 27× · PMID 36065205 · DOI 10.1016/j.crimmu.2022.08.004
Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection
Dalai SC, Dines JN, Snyder TM, Gittelman RM, et al · · 2021 · cited 8× · DOI 10.1101/2021.01.06.21249345

Verify or expand the search:

Other recruiting trials for Coronavirus Disease (COVID-19)

Currently open trials in the same condition.

NCT06667700 — A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are Hi · Phase 3 · recruiting

Other Adaptive Biotechnologies trials

Trials by the same sponsor.

NCT05769829 — ImmuneSense™ IBD Study · terminated
NCT05255354 — Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy · recruiting
NCT05112874 — ImmuneSense™ COVID-19 Cross-Reactivity Study · withdrawn
NCT05054088 — ImmuneSense COVID-19 Variant Study · completed
NCT04545333 — The clonoSEQ® Watch Registry · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04583982 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Adaptive Biotechnologies
Last refreshed: 15 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04583982.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing